Public Summary Documents - December 2019 PBAC meeting

9 April 2020 - The Public Summary Documents relating to the December 2019 PBAC meeting are now available. ...

Read more →

Public Summary Documents - November 2019 PBAC meeting (supplement)

26 March 2020 - Additional insights from the second round of public summary documents (first time rejections and deferrals). ...

Read more →

Public Summary Documents - November 2019 PBAC meeting

25 March 2020 - Insights from the second round of public summary documents (first time rejections and deferrals). ...

Read more →

PBAC Public Summary Documents - November 2019 meeting (first time rejections and deferrals)

20 March 2020 - The public summary documents (first rejections and deferrals) from the November 2019 PBAC meeting are now available. ...

Read more →

ICER releases draft evidence report on obeticholic acid for non-alcoholic steatohepatitis

19 March 2020 - Public comment period on preliminary draft now open until 24 June 2020; requests to make oral comment ...

Read more →

Drug Utilisation Sub-Committee outcome statement

18 March 2020 - The outcome statement from the February 2020 Drug Utilisation Sub-Committee meeting is now available. ...

Read more →

ICER releases evidence report on treatments for sickle cell disease

12 March 2020 - Three new treatments use different mechanisms to improve patient outcomes, offering important options for patients. ...

Read more →

Standardised redactions to Public Summary Documents – nominations open for participation in the final trial, and implementation from July 2020

5 March 2020 - The Department is now seeking nominations from sponsors with submissions due to be considered at the ...

Read more →

ICER issues final report and policy recommendations on acute treatments for migraine

25 February 2020 - Evidence on new agents lasmiditan, ubrogepant, and rimegepant judged inadequate to demonstrate superiority over more affordable triptans. ...

Read more →

ICER releases draft evidence report on therapies for cystic fibrosis

20 February 2020 - Public comment period now open until 18 March 2020; requests to make oral comment during public meeting ...

Read more →

Serving public health paramount in a successful 2019 for FDA’s generic drug program

19 February 2020 - Safe, effective, high-quality generic drugs play a vital role in the U.S. health care system.  ...

Read more →

PBAC Public Summary Documents - August 2019 intracycle meeting

31 January 2020 - All Public Summary Documents from the August 2019 PBAC intracycle meeting are now available. ...

Read more →

ICER releases draft evidence report on therapies for sickle cell disease

23 January 2020 - ICER’s ongoing assessment emphasises that policy makers will need to consider, in addition to traditional measures ...

Read more →

Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study

17 January 2020 - Failure to report the results of a clinical trial can distort the evidence base for clinical practice, ...

Read more →

ICER releases evidence report on acute treatments for migraine

10 January 2020 - Lasmiditan, rimegepant, and ubrogepant all perform better than placebo, but evidence is not adequate to distinguish among ...

Read more →